|
Aug 9
|
The Smartest Growth Stocks to Buy With $1,000 Right Now
|
|
Aug 8
|
5 Top Stocks to Buy in August
|
|
Aug 7
|
The RMR Group Announces $1.0 Billion Refinancing of Vertex Pharmaceuticals’ Headquarters in Boston Seaport District
|
|
Aug 7
|
Vertex Pharmaceuticals (VRTX) Reports Strong Q2 2025 Revenue Growth with US$2,965 Million
|
|
Aug 6
|
Vertex Pharmaceuticals (VRTX) Hits New All-Time Low on Failed Clinical Trial
|
|
Aug 6
|
Snap downgraded, Leidos upgraded: Wall Street's top analyst calls
|
|
Aug 6
|
Vertex Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations
|
|
Aug 6
|
S&P Futures Gain With Focus on Earnings and Fed Speak
|
|
Aug 6
|
Vertex’s Journavx successor culled after falling short in Phase II trial
|
|
Aug 6
|
7 Reasons Why Vertex Pharmaceuticals Is a No-Brainer Stock to Buy on the Dip
|
|
Aug 5
|
Why Vertex Pharmaceuticals (VRTX) Stock Is Trading Lower Today
|
|
Aug 5
|
VRTX: Vertex Shares Tank After Pain Drug Flop in Key Trial
|
|
Aug 5
|
CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption
|
|
Aug 5
|
Top Stock Movers Now: Gartner, Axon Enterprise, Palantir, and More
|
|
Aug 5
|
VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study Goal
|
|
Aug 5
|
Stocks See Support from Strong Earnings and Rate Cut Speculation
|
|
Aug 5
|
Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug
|
|
Aug 5
|
Vertex Pharmaceuticals, Kyndryl, Caterpillar: Trending Tickers
|
|
Aug 5
|
Stock Market Today: Dow Rises Ahead Of Key Data; Palantir Surges On Earnings (Live Coverage)
|
|
Aug 5
|
Vortex Energy Mobilizes Field Crews for ANT Survey at Robinsons River Salt Project
|